APP下载

缬沙坦对高脂大鼠模型血脂水平的影响及抗炎分子机制分析

2014-09-17邱樑李晟姚琪苏郁达

中国医药导报 2014年16期
关键词:炎症因子血脂效果

邱樑 李晟 姚琪 苏郁达

[摘要] 目的 探讨在高脂血症大鼠模型中应用缬沙坦进行干预治疗对血脂的影响,并分析其抗炎分子机制。 方法 选取30只健康雄性Wistar大鼠,利用随机数字表法进行分组,分别设为A组、B组和C组,每组各10只。A组为对照组,给予常规饮食;B组和C组均为高脂血症模型组,两组均进食高脂饲料达8周,其中C组在第9周开始进行缬沙坦14 mg/(kg·d)药物灌肠处理,而B组则采取生理盐水灌肠。待喂养第8周末,采取三组大鼠内眦静脉血,检测其血脂水平和超敏C反应蛋白(hs-CRP)。待第18周末(缬沙坦干预治疗10周后),利用2%戊巴比妥钠行腹腔麻醉后,采取三组大鼠心室内血液,检测血脂水平、血清炎症因子;并留取主动脉全长用于提取RNA,一部分用于HE染色观察动脉内膜的改变。 结果 第8周末,B、C两组总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)[B组:(10.18±2.06)、(1.71±0.25 )mmol/L;C组:(9.32±2.22)、(1.74±0.39)mmol/L]明显高于A组[(2.07±0.43)、(1.12±0.26)mmol/L],差异均有统计学意义(均P < 0.05);第18周末,B、C两组的TC值[11.10±2.54)、(10.02±1.99)mmol/L]明显高于A组[(2.58±0.22)mmol/L], B组血清炎症因子hs-CRP、TNF-α、IL-6、IL-8[(166.11±21.09)mg/L、(1.55±0.18)μg/L、(166.85±54.37)ng/L、(410.22±29.27)ng/L]明显高于A组[(85.31±28.51)mg/L、(0.84±0.25)μg/L、(90.07±30.34)ng/L、(270.82±20.11)ng/L],差异均有统计学意义(均P < 0.05)。经缬沙坦干预治疗10周后,C组血清中hs-CRP、TNF-α、IL-6[(98.25±12.77)mg/L、(1.18±0.30)μg/L、(92.26±29.37)ng/L]均低于B组,差异均有统计学意义(均P < 0.05),缬沙坦干预治疗18周后,B组hs-CRP mRNA、TNF-α mRNA和IL-6 mRNA[(2.76±0.40)、(3.21±0.46)、(2.33±0.35)]明显高于A组[(1.00±0.04)、(1.01±0.03)、(1.02±0.03)]和C组[(2.76±0.40)、(3.21±0.46)、(2.33±0.35)],差异均有统计学意义(均P < 0.05)。 结论 缬沙坦能够降低高脂血症大鼠模型的血脂水平,抑制促炎因子释放,在抗动脉粥样硬化方面发挥出可观的效果。

[关键词] 高脂大鼠;缬沙坦;血脂;炎症因子;效果

[中图分类号] R543.1[文献标识码] A[文章编号] 1673-7210(2014)06(a)-0020-04

Analysis of the influence of Valsartan on the lipid level and its molecular mechanism of anti-inflammation in model rats with high fat

QIU Liang1 LI Sheng2 YAO Qi1 SU Yuda3

1.Department of Cardiology, the People's Hospital of Shengzhou, Zhejiang Province, Shengzhou 312400, China; 2.Department of Cardiology, the First Affiliated Hospital of Wenzhou Medical College, Zhejiang Province, Wenzhou 325000, China; 3.Department of Neurology, the Second Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang Province, Hangzhou 310009, China

[Abstract] Objective To explore the intervention effect on blood lipid of valsartan for the rat model with hyperlipidemia, and to explore the anti-inflammatory molecular mechanism. Methods 30 healthy male Wistar rats were selected by random number table method and they were divided into group A, B and C, 10 rats in each group. Group A was given routine diet as the control group, group B and C were fed with high fat diet for up to 8 weeks, as hyperlipidemia model group. Group C was treated with Valsartan enema 14 mg/kg per day at the 9 weeks, while group B was taken normal saline enema. At the end of 8 weeks after feed, the blood lipid level and high sensitive C reactive protein (hs-CRP) were detected by angular vein blood. At the end of 18 weeks after feed (Valsartan treatment after 10 weeks). After intraperitoneal cavity anesthesia with 2% Pentobarbital Sodium, the lipid levels, serum inflammatory factors were detected by ventricular blood, and RNA was extracted by the aorta and part of them was used for HE staining to observe arterial intimal changes. Results At the end of 8 weeks, TC, LDL-C of group B and C [group B:(10.18±2.06), (1.71±0.25) mmol/L; group C:(9.32±2.22), (1.74±0.39) mmol/L] were higher than those of group A [(2.07±0.43), (1.12±0.26) mmol/L], the differences were statistically significant (all P < 0.05). At the end of 18 weeks, TC of group B and C [(11.10±2.54), (10.02±1.99) mmol/L] were higher than that of group A [(2.58±0.22) mmol/L], hs-CRP, TNF-α, IL-6, IL-8 of group B [(166.11±21.09), (1.55±0.18), (166.85±54.37), (410.22±29.27) ng/L] were higher than those of group A [(85.31±28.51) mg/L, (0.84±0.25) μg/L, (90.07±30.34) ng/L, (270.82±20.11) ng/L], the differences were statistically significant (all P < 0.05). Treated with Valsartan after 10 weeks, hs-CRP, TNF-α, IL-6 of group C [(98.25±12.77) mg/L, (1.18±0.30) μg/L, (92.26±29.37) ng/L] were lower than those of group B (P < 0.05). At end of 18 weeks, hs-CRP mRNA, TNF-α mRNA and IL-6 mRNA of group B [(2.76±0.40), (3.21±0.46),(2.33±0.35)] were higher than group A [(1.00±0.04), (1.01±0.03), (1.02±0.03)] and group C [(2.76±0.40), (3.21±0.46), (2.33±0.35)], the differences were statistically significant (all P < 0.05). hs-CRP mRNA, TNF-α mRNA, IL-6 mRNA were lower than those of group B (P < 0.05). Conclusion Valsartan can reduce the blood lipid level of the model of hyperlipidemia rats, inhibit proinflammatory cytokine release, which plays a significant effect on anti atherosclerosi.

[Key words] High fat rats; Valsartan; Blood lipid; Inflammatory factor; Effect

随着我国人口老龄化进程的加快,再伴随人们生活水平的改善,在日常饮食结构方面出现了极大的改变,其中高脂、高蛋白饮食逐渐占据了人们的饮食习惯[1]。而与此相伴行的是高脂血症和动脉粥样硬化(AS)的发生率逐年攀升,AS又在心脑血管疾病的发生、发展过程中扮演着关键角色,所以如何防止AS已经引起全世界医务人员的广泛关注[2]。近年来,关于AS的基础研究越来越多,其中有文献指出,AS不是单纯由血脂沉积于血管壁引发的病变,在该病的发病过程中,炎症因子也发挥了不可忽视的作用[3]。……

登录APP查看全文

猜你喜欢

炎症因子血脂效果
按摩效果确有理论依据
血脂常见问题解读
迅速制造慢门虚化效果
你了解“血脂”吗
抓住“瞬间性”效果
胸腹腔镜微创手术与传统开胸手术对食管癌患者术后肺功能、炎症因子水平的影响
阿托伐他汀强化降脂对急性脑梗死患者疗效与炎症因子的影响
血必净治疗重症肺炎的效果观察及对炎症因子和氧化、抗氧化因子的影响
氨氯地平联合阿托伐他汀对高血压合并高血脂患者内皮功能的影响
模拟百种唇妆效果